AMCP

PARTNERSHIP FORUM

No. 3 — 2020

Biosimilars: Policy, Practice, and Post Marketing Surveillance to Support Treatment and Coverage Decisions

DEC. 15–16, 2020 | VIRTUAL

as of Jan. 4, 2021

WELCOME

Welcome to AMCP's final Partnership Forum of 2020. We appreciate that you will be spending the next two days with us to identify key actions that can support the further development and use of biosimilars in the U.S. health care system.

Biologics, including biosimilars, offer a critical opportunity for expanding patient access to medicines while simultaneously reducing health care costs through a competitive marketplace. However, biosimilar adoption in the United States is significantly slower than in other countries.

AMCP's focus is on addressing the practice and regulatory hurdles that hinder utilization of biosimilars and ensuring health care decision makers have the evidence they need to evaluate the safety and effectiveness of these therapies.

During this AMCP Partnership Forum, we will discuss the policy, practice, and post-marketing surveillance activities that support treatment and coverage decisions for biosimilars. We will also analyze the barriers to biosimilar adoption, including gaps in provider knowledge and the need to generate more real-world evidence to inform treatment and coverage decisions.

To facilitate a successful dialogue, I am pleased to welcome a variety of participants to this AMCP Partnership Forum, including payers, pharmacists, integrated delivery system leaders, health economists and analysts, academicians, patient care providers, pharmaceutical manufacturers, and other key decision makers.

This AMCP Partnership Forum would not be possible without the generous support of our sponsors: Amgen, the Association for Accessible Medicines, Boehringer Ingelheim, Fresenius Kabi, Johnson & Johnson, Novo Nordisk, Pfizer, Sandoz, and Takeda.

Following this event, AMCP will produce proceedings documenting our findings and recommendations in an upcoming issue of AMCP's *Journal of Managed Care + Specialty Pharmacy,* which is widely disseminated to decision makers around the country.

I look forward to your participation in this important AMCP Partnership Forum.

Sincerely,

Susan A. Cantrell, RPh, CAE
AMCP CEO

MODERATOR

Clifford Goodman, PhD
Senior Vice President
The Lewin Group

Clifford Goodman, PhD, is a senior vice president at The Lewin Group. He has 30 years of experience in health technology assessment, evidence-based health care, health economics, and aspects of health care innovation, regulation, and payment. Dr. Goodman often serves as a health policy issues moderator and facilitator of expert panels and advisory boards. He served as chair of the CMS Medicare Evidence Development & Coverage Advisory Committee and president of the professional society, Health Technology Assessment International. He received his Doctorate in Philosophy from The Wharton School of the University of Pennsylvania and degrees from Georgia Tech and Cornell.

AGENDA

TUESDAY, DEC. 15

12-5pm ET

Welcome and introductions

Presentation: Perspectives on biosimilars

Panel discussion: Exploring the challenges and facts about biologics and biosimilars in the United States

Breakout session 1: Strategies and messaging to increase access and adoption of biosimilars

Report out and discussion

HOSTED BY AMCP IN PARTNERSHIP WITH

AGENDA

WEDNESDAY, DEC. 16

12-5pm ET

Welcome and day 1 debrief

Panel discussion: What is working in the world of biosimilars?

Breakout session 2: Strategies and real-world evidence needs and opportunities to help with biosimilar adoption

Report out and discussion

Forum summary and close

PARTICIPANTS

Christina Barrington, RPh, PharmD

Vice President of Pharmacy Programs
Priority Health

Christina Barrington, RPh, PharmD, has more than 20 years of managed care experience and is currently the vice president of pharmacy programs for Priority Health, where she is responsible for setting strategy for the pharmacy department and managing the pharmaceutical services budget across the organization. In addition to her role in pharmacy management, Dr. Barrington has conducted extensive research into the impact of value-based benefit designs and is a pioneer in risk-based contracting strategies. She has presented her research and innovative contracting strategies at a variety of conferences. Additionally, she has served as the vice-chairman of the board of managers for the Illinois Foundation of Quality Health Care and is currently a member of the URAC Measures Advisory Research Group. As an active member of AMCP since 1996, Dr. Barrington has held the office of president of the Midwest affiliate for two terms and currently serves on the finance committee.

Diana Brixner, RPh, PhD, FAMCP

Professor
Department of Pharmacotherapy

Diana Brixner, RPh, PhD, FAMCP, is the executive director at the University of Utah Pharmacotherapy Outcomes Research Center. She is also a research associate at the Institute of Public Health, Medical Decision Making, and Health Technology Assessment in the Department of Public Health and Health Technology Assessment at University of Miami Information Technology. Her appointment supports her international collaborations in oncology research, personalized medicine, and value assessment. Dr. Brixner is a founding member of the Health Policy and Science Council, where she also served on the executive board. She is also a past president of the International Society of Pharmacoeconomics and Outcomes Research. Dr. Brixner is a long-standing member and past president of AMCP. She currently serves as a director on the board for the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC).

Mary Jo Carden, JD

Head of Policy
Sandoz

Mary Jo Carden, JD, serves as the head of policy for Sandoz. She joined Sandoz in Sep. 2019 after serving in various capacities at AMCP for six years, including as vice president of government and pharmacy affairs. She also has experience in policy and government affairs in PBMs, retail pharmacies, and long-term care pharmacies. She holds a Bachelor of Science from University of Pittsburgh and a Juris Doctor degree from Catholic University in Washington, D.C.

PARTICIPANTS

Jack Cox

Senior Director
Nova Nordisk Inc.

Jack Cox is a senior director of market access and trade strategy at Novo Nordisk. Jack as more than 30 years experience in pharmaceutical, biotech, and distribution channels and has worked in marketing, operations, business development, and market access. He joined Novo Nordisk in 2012 and is currently responsible for payer marketing and pricing/contracting strategy for the insulin and biopharm franchise teams. Prior to joining Novo Nordisk, he worked at Accredo Specialty Pharmacy as vice president, business development where he led the strategy development for pipeline products, managed manufacturer relations, and contract negotiations. He earned his Bachelor of Science from Bowling Green State University and his Master in Business Administration from Marshall University.

Joe Eggler

Senior Director, Market Access
Account Management
Fresenius Kabi

Joe Eggler has 30 years of health care experience in both pharmaceutical and molecular diagnostics. During this time, he has held positions ranging from sales, marketing, new product development, sales management, payer account management, executive level commercial operations, market access, and patient and provider support programs. He has worked in various companies starting with TAP pharmaceuticals, Prometheus Laboratories, Provista Diagnostics, Lash Group, and Fresenius Kabi. Joe is currently the senior director, payer account management at Fresenius Kabi and leads the team that prepares the launch of several biosimilars.

Erika Emerson

Executive Director
Diabetes Leadership Council

Erika B. Emerson is executive director of the Diabetes Leadership Council. She has more than 20 years of health policy and advocacy experience, including health care and pharmaceutical public policy, issues management, strategic communications, and stakeholder relations. Her pharmaceutical industry experience and knowledge of the U.S. health care system lend unique insight on state and federal policies impacting access, quality and value of care and coverage for people with chronic conditions. Erika holds a Masters in Public Policy from the Harvard Kennedy School and a bachelor's degree in journalism and political science from the University of Wisconsin-Madison.

PARTICIPANTS



Alison Falb, JD

Regulatory Counsel
FDA

Alison Falb, JD, is a regulatory counsel in the FDA Center for Drug Evaluation and Research's (CDER) Office of Therapeutic Biologics and Biosimilars, which oversees the development and implementation of regulatory policy related to biosimilar, interchangeable, or other therapeutic biologic products. Prior to joining the Office of Therapeutic Biologics and Biosimilars, Alison was a senior advisor at the Center for Medicare and Medicaid Innovation at CMS where she led policy development for specialty care and episode-based payment models under the Medicare Access and CHIP Reauthorization Act of 2015 statute and designed and implemented alternative payment models including the Oncology Care Model.

Anna Hyde

Vice President of Advocacy and Access
Arthritis Foundation

Anna Hyde is the vice president of advocacy and access at the Arthritis Foundation. She oversees grassroots engagement and both the federal and state legislative programs. Her focus is to raise the visibility of arthritis as a public health priority; build support for federal and state legislation that ensures access to affordable, high-quality health care; and enhance patient engagement in the policy-making process. Anna worked as senior manager for federal affairs at the American Congress of Obstetricians and Gynecologists. She began her health policy career as a congressional fellow for Energy and Commerce Committee members, where she drafted legislation and staffed committee activities. Anna received a Bachelor of Arts in history from Southern Methodist University and Master in Arts in political science from American University.

Jim Kenney, RPh, MBA

President
JTKENNEY LLC

Jim Kenney, RPh, MBA, is founder and president of JTKENNEY LLC, a managed care pharmacy consulting practice in Waltham, Mass. Jim worked for Harvard Pilgrim Health Care for 38 years in pharmacy management, most recently as the manager of specialty and pharmacy contracts. Jim has received national recognition for the development of value and outcomes-based contracts for pharmacy and medical products. Jim is a pharmacy preceptor for the Massachusetts College of Pharmacy and Health Sciences. He currently serves on the Massachusetts Pharmacists Association Government and Legislative Affairs Committee. Jim is currently immediate past-president of AMCP, where he has been an active member for 30 years and has served on several committees.

PARTICIPANTS

Troy Koch, PharmD, MBA

Account Medical Lead
Takeda Pharmaceuticals

Troy Koch, PharmD, MBA, is currently a director, account medical lead for Takeda Pharmaceuticals. In his role, he engages in scientific exchange regarding Takeda products with some of the top corporate and national health plan and PBMs. Dr. Koch has an extensive career in the pharmaceutical and managed care industries, holding positions previously with Humana, Medimpact, and Hobart Core (now Precision for Value). He earned a Doctor of Pharmacy degree from the University of Kentucky, a Master of Business Administration from the University of Louisville, and completed a residency in managed care pharmacy with Humana Inc.

April Kunze, PharmD

Senior Director, Clinical Formulary Development and Trend Management Strategy
Prime Therapeutics

April Kunze, PharmD, is the senior director of formulary development and trend management strategy at Prime Therapeutics (Prime) and is responsible for evaluating and communicating clinical and financial decision making models for multiple formularies. She leads trend management activities and analyzes the value of formulary changes, utilization management, and other clinical programs. She also oversees Prime's pipeline division and proactively develops strategies to manage new, high-cost drug approvals. Prior to joining Prime in 2004, Dr. Kunze worked for a home infusion company where she gained insights to many specialty drugs and disease states. She also acquired expertise in clinical patient management.



Paul Lakomski, BS, RPh, MBA

Pharmacy Services Manager
Aetna / CVS

Paul G. Lakomski, RPh MBA, is a pharmacy services manager for Aetna/ CVS. In this role, he supports Aetna's clients in trend management, clinical programs, and benefit design for pharmacy. Previously, Paul was a director of account management-MCO for Catamaran; pharmacy director for Empire Blue Cross Blue Shield and Anthem New Hampshire; director account management regional for WellPoint NextRx; drug utilization review director, pharmacy director, and director of network management for Excellus Blue Cross Blue Shield. He is as subject matter expert regarding clinical programs, pharmacy cost drivers, trends, and pharmacy/ medical benefit products.

PARTICIPANTS

Jeffrey (Jeff) Larson, RPh, MS, MBA

Clinical Director
CVS Health

Jeff Larson, RPh, MS, MBA, is a clinical director and supervises a team of clinical advisors who are responsible for the clinical programs and clinical management services provided to CVS Health clients in the health plan market segment. Jeff joined CVS Health in 1994 and is currently based in Minneapolis. Prior to joining the company, Mr. Larson completed a two-year management residency at the VA Medical Center, Minneapolis concurrent with graduate work at the University of Minnesota. Jeff earned his Bachelor of Science in pharmacy from North Dakota State University, his Master of Science in hospital pharmacy from the University of Minnesota, and a Master in Business Administration from the University of St. Thomas. He is an active member of AMCP and has served on multiple AMCP committees, including former committee leadership positions.

Molly Billstein Leber, PharmD, BCPS, FASHP

Associate Director, Drug Use Policy and Formulary Management
Yale New Haven Health

Molly Billstein Leber, PharmD, MBA, BCPS, FASHP, is the associate director of drug use policy and formulary management at Yale New Haven Health System. In this role, she is responsible for standardizing safe and cost-effective medication therapy across the system.

Hannah Lynch, MPS

Associate Director, Federal Government Relations and Health Policy
National Psoriasis Foundation (NPF)

Hannah Lynch, MPS, is the associate director of federal government relations and health policy for NPF. In this role, she directs NPF's legislative and regulatory efforts at the federal level, develops the foundation's federal policy positions, and represents NPF on several national coalitions. Prior to her current role, she worked for the Biotechnology Innovation Organization (BIO) as manager of health care policy and research, focusing primarily on Medicare, Medicaid, and drug reimbursement policy. She also spent time with the National Alliance of State Health CO-OPs and on Capitol Hill. Hannah received a Master of Professional Studies in legislative affairs from The George Washington University, and a Bachelor of Science in political science (pre-law) from The University of North Carolina at Greensboro.

PARTICIPANTS

George Mayzell, MD, MBA

President
Empowered Healthcare

George Mayzell, MD, MBA, is the founder and president of Empowered Healthcare, which specializes in population health, care management redesign, clinical variation, and clinical integration. Dr. Mayzell was the past chief clinical officer of Vizient Southeast and senior vice president/chief medical officer and chief clinical integration officer for AMITA Health. AMITA Health is a joint operating company formed in Feb. 2015 by Adventist Midwest Health and Alexian Brothers Health System, encompassing nine hospitals and an extensive physician provider network of more than 3,000 physicians. Dr. Mayzell joined Adventist Midwest Health in Jan. 2013 after serving as CEO of Health Choice and senior vice president of Methodist Le Bonheur Healthcare in Memphis, Tenn. He received his medical degree from Rutgers and his Master in Business Administration from Jacksonville University.



Dorothy McCabe, PhD, FCP

Executive Director, CDMA, Specialty Care
Boehringer Ingelheim Pharmaceuticals Inc.

Dorothy McCabe, PhD, FCP, is executive director of clinical development and medical affairs, specialty care organization at Boehringer Ingelheim Pharmaceuticals. She provides medical/scientific, technical, and strategic directions to the plans, programs, and procedures within the inflammation therapeutic and indication areas with a focus on biosimilar development. She has over 35 years experience leading product development and innovation in both small-molecule and biological compounds. Dr. McCabe has broad multidisciplinary science and medicine expertise. She has held leadership positions in medical affairs and new product development at several pharmaceutical companies and has been involved in many regulatory interactions and strategies leading to commercial success.

Corey McEwen, PharmD, MS

Director, Oncology Pharmacy Services
Massachusetts General Hospital

Corey McEwen, PharmD, MS, is the director of oncology pharmacy services at Massachusetts General Hospital. In this role, he oversees clinical and operational pharmacy services for the oncology pharmacy service line including inpatient oncology pharmacy, the main campus infusion center, and two regional infusion centers in the greater Boston area. Additionally, Dr. McEwen has oversight of the pharmacy clinical trials programs which support the largest hospital-based research program in the country. He completed his two-year health system pharmacy administration residency at the Cleveland Clinic in Cleveland. He received Master of Science in health system pharmacy administration from Northeast Ohio Medical University and received his Doctor of Pharmacy from the University of Mississippi.

PARTICIPANTS

Ann McNamara, PharmD

Director of Clinical Development
Fairview

Ann McNamara, PharmD, is director of clinical development within the specialty development team at Fairview Specialty Pharmacy. Dr. McNamara has worked at Fairview Specialty Pharmacy since Sep. 2004. She is responsible for the direction and oversight of clinical development, therapy management, adherence programs, waste management strategies, clinical reporting, and specialty pipeline monitoring. She provides clinical support for payer strategies, payer quarterly business reviews, and manufacturer initiatives. Prior to her current position, she was the director of the clinical specialist team at Express Scripts. She received her Doctor of Pharmacy at the University of Minnesota and completed an ambulatory residency at St. Paul Ramsey Medical Center.

Therese Mulvey, MD, FASCO

Director Quality Safety and Value
MGH Cancer Center
MGH

Therese Mulvey, MD, FASCO, is a medical oncologist specializing in breast cancer at Massachusetts General Hospital (MGH). She is the director of quality, safety, and value for the cancer center and its nine affiliated network sites. She recently co-chaired the MGH Oncology Pharmacy and Therapeutics Safey Committee (PTSC) and serves on the MGH Brigham Oncology PTSC. Dr. Mulvey is an active volunteer for the American Society of Clinical Oncologists, where she currently serves as the immediate past chair of its quality-of-care council and is a member of the telehealth task force. She is the author of many papers concerning care delivery and improving cancer care.

Farhana Naz, BS

Senior Director Strategy
Fresenius Kabi

Farhana Naz, BS, has more 25 years of experience in the health care industry analyzing evidence and cost value propositions for drug coverage decisions. Her experience includes pharmaceutical product strategy support at Anthem, Express Scripts, Aetna, Cardinal Health, and Proctor & Gamble pharmaceuticals.

PARTICIPANTS

Sonia Oskouei, PharmD, BCMAS, DPLA

Vice President, Biosimilars
Cardinal Health

Sonia T. Oskouei, PharmD, BCMAS, DPLA, serves as the vice president of biosimilars for Cardinal Health, where she leads the organization's biosimilar strategy. Previously, Dr. Oskouei served as vice president of innovation and digital health at Premier Inc. and led the national biosimilars strategy on behalf of 4,000 hospitals and more than 175,000 other provider types. Prior to her work at Premier, Dr. Oskouei oversaw pharmacy purchasing and procurement at Novant Health, a four-state integrated delivery network. She received her Doctor of Pharmacy from Belmont University, and completed post-graduate residencies in clinical pharmacy and health system pharmacy administration.

Gary Owens, MD

President
Gary Owens Associates

Gary Owens, MD, was actively involved in the managed care movement of the 1990s, which evolved to the current era of health care coverage and payment reform. Dr. Owens served as the vice president of medical management and policy at Independence Blue Cross for 22 years. Forming his own consulting practice in 2007, Dr. Owens provides strategic and tactical consulting services to a wide range of clients, including pharmaceutical manufacturers, device manufacturers, and other developers of new technology. Dr. Owens is the past chair of the Arthritis Foundation of Eastern Pennsylvania, where he was a former member of the foundation's northeast regional board of directors. In addition. Dr. Owens was the first physician to serve as a board member for AMCP from 2014 to 2018.

Chad Pettit, MBA

Executive Director, Marketing
Amgen

Chad Pettit, MBA is the executive director of marketing for Amgen's biosimilars business unit and leads the global biosimilars commercial team in developing global launch strategy for Amgen's portfolio of biosimilar medicines. He serves as a liaison with the biopharmaceutical industry on policy matters in biosimilars, a rapidly growing segment of the Amgen business. With his global experience, Chad has broad perspective and is recognized as an expert on biosimilar commercialization, market access for biosimilars, and the policy measures required to facilitate cost savings for patients and the health care system over the long run. Chad received his Master in Business Administration from the University of California Los Angeles, Anderson School of Management, and holds a Bachelor of Science in chemical engineering from the University of California Davis.

PARTICIPANTS

Laura Pizzi, PharmD, MPH

Director and Professor
Rutgers University—Health Outcomes, Policy, and Economics (HOPE) Program

Laura Pizzi, PharmD, MPH, is a seasoned evaluation scientist and professor and director of the Center for Health Outcomes, Policy, and Economics at Rutgers University. She has led interdisciplinary teams to develop and conduct cost and outcome analyses on pharmacological therapies as well as a variety of non-pharmacological interventions. She has testified before the U.S. House of Representatives Committee on Ways and Means on Medicare overspending in beneficiaries with end-stage renal disease. Dr. Pizzi is editor in chief of Value and Outcomes spotlight, member of the editorial board for PharmacoEconomics, deputy editor of American Health and Drug Benefits, co-chair of the Cross-Council Workgroup on Competencies for New Professionals in Health Economics and Outcomes Research, and chair of the Common Economic Measures Workgroup for a new CDC-funded multi-center grant on glaucoma.

Ronald Piervincenzi, PhD

Chief Executive Officer
United States Pharmacopeia (USP)

Ronald T. Piervincenzi, PhD, has served as chief executive officer of USP since 2014. Under his leadership, USP has modernized its operations and launched innovative new science, including in digital medicine, cutting-edge manufacturing technologies, and advanced biologics. Before joining USP, Dr. Piervincenzi served as vice president of development sciences with Biogen Idec Inc. and was a partner and leader in McKinsey & Company's global pharmaceutical and medical products practice for more than 12 years. Dr. Piervincenzi earned his Doctorate in Philosophy and Master of Science from Duke University in biomedical engineering, with research focused on protein engineering.

Jim Rebello

Vice President, Formulary Strategy
Magellan Rx Management

Jim Rebello is currently the vice president of formulary strategy for Magellan Rx Management underneath the MRx Specialty division. He works with payers to provide valuable solutions for formulary management to find savings in the high-trending specialty space on both the pharmacy and medical benefits. Jim is a pharmacist with more than a decade of managed care experience working directly with health plans and employers. Jim received his Doctor of Pharmacy at the University of Rhode Island and also served in the U.S. Air Force.

PARTICIPANTS

Carly Rodriguez, PharmD, FAMCP

Pharmacy Director, Clinical Innovation
Moda Health

Carly Rodriguez, PharmD, FAMCP, is pharmacy director, clinical innovation for Moda Health. She provides strategic leadership for clinical initiatives, operations, innovation, and the integration and management of medications across pharmacy and medical benefits. Her areas of expertise include formulary management, cost-savings and utilization management strategies, specialty drug management, benefit design, and medical pharmacy. She has presented to a variety of audiences on important topics in managed care, such as specialty pharmacy, data integration, oncology, and trend management. Dr. Rodriguez received her Doctor of Pharmacy from the University of Washington, School of Pharmacy, along with a certificate in biomedical and regulatory affairs. She was recognized as a fellow of AMCPin 2019 for exceptional contribution, commitment, and sustained excellence in managed care pharmacy.



Elizabeth Sampsel, PharmD, MBA, BCPS

Clinical Program Manager
MedImpact Healthcare Systems Inc.

Elizabeth Sampsel, PharmD, MBA, BCPS, provides clinical consultative services for MedImpact to health plans, including P&T support and quality measure optimization to assist clients with achieving overall improved health outcomes at the lowest possible net cost. Dr. Sampsel has supported clients over numerous lines of business, including commercial, government programs, and employer groups. Dr. Sampsel has more than 20 years of pharmacist experience in various settings, including PBM, health plan, and health systems and with the FormularyDecisions platform. She currently serves on the AMCP legislative and regulatory advisory committee, leads the COVID-19 subcommittee, and has been a national judge for the AMCP Foundation P&T Competition for 10 years.

Marissa Schlaifer, MS, RPh

Vice President, Policy and Regulatory Affairs
OptumRx

Marissa Schlaifer, MS, RPh, currently serves as vice president, policy and regulatory affairs at OptumRx, where she's responsible for public policy related to OptumRx's PBM and home delivery, specialty, home infusion, compounding, and community mental health pharmacies. Prior to her current position, she worked as an independent consultant focused on health care policy analysis, issue advocacy, practice advancement and business development. Previously, Marissa served as the head of policy in the government affairs department for a major PBM and pharmacy innovation company, and as director of pharmacy and regulatory affairs at AMCP. Marissa currently serves as AMCP President.

PARTICIPANTS

Christine Simmon, JD

Senior Vice President, Policy and Strategic Alliances and Executive Director, Biosimilars Council
Association for Accessible Medicines (AAM)

Christine Simmon, JD, joined the Association for Accessible Medicines in 2012 as the senior vice president of policy and strategic alliances and most recently was named executive director of AAM's Biosimilars Council, which was founded in 2015. Christine is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups. Christine previously served as vice president of policy, public affairs and development at AAM from 2002 to 2006. Before rejoining the association, she was the senior director of public policy for CVS Caremark, where she was the policy lead for the integrated retail, convenient care clinic, and pharmacy benefit manager enterprise at both the state and federal levels.

Eva Temkin, JD

Acting Director for Policy
FDA, CDER, Office of Therapeutics and Biologics

Eva Temkin, JD, is the acting director for policy in the FDA CDER's Office of Therapeutics and Biologics. She oversees the development and implementation of policy related biological products. Eva leads FDA's Biosimilar Action Plan, which outlines the administration's plans for encouraging innovation and competition among biologics and the development of biosimilars. She also works on patient access. Previously, Eva was associate chief counsel for drugs in FDA's Office of Chief Counsel and counseled on numerous biomedical products issues, including expedited pathways, data development questions, and evidentiary standards to over-the-counter monograph reform. Eva was a former litigator at Cravath, Swaine & Moore LLP and Robbins, Russell, Englert, Orseck, Untereiner & Sauber LLP. She was also a law clerk in the U.S. District Court for the Eastern District of New York.

Jaap Venema, PhD

Executive Vice President and Chief Science Officer
USP

Jaap Venema, PhD, is the executive vice president and chief science officer for USP, where he leads the organization's scientific strategy and development of quality standards for medicines, dietary supplements, food ingredients, and health care practice. Dr. Venema oversees implementation of the USP Science Quality Framework, which grounds quality standards development in pharmaceutical science to increase public trust in medicines. He guides exploration of emerging technologies that may inform future quality standards; serves as chair of USP's council of experts; and oversees collaborations with other pharmacopeial and scientific groups. Dr. Venema previously served in scientific leadership positions at Solvay and AbbVie (formerly Abbott Laboratories). Dr. Venema earned a master's degree in chemistry from the Free University of Amsterdam, and a Doctorate of Philosophy in biochemistry and molecular biology from Leiden University in the Netherlands.

PARTICIPANTS

Randy Vogenberg, PhD, RPh

Principal and Board Chair
Institute for Integrated Healthcare (IIH) and Employer-Provider Interface Council (EPIC)

Randy Vogenberg, PhD, RPh, is principal of IIH. Previously, he was the senior vice president and thought leader for Aon Consulting North America. He currently serves as board chair for the EPIC for the Hospital Quality Foundation; co-leader for the National Employer Biologics & Specialty Initiative, Midwest Business Group on Health; and fellow for the Foundation for HealthSmart Consumers. His work for self-funded employers include innovative contracting, compliance, and holistic care cost management or research to drive high performing plans. His expertise in commercial/employer benefits and care delivery issues has produced several books, publications, and presentations in peer-reviewed and non-peer reviewed venues. He continues collaborations with various universities, including three adjunct faculty appointments and guest lectureships on his areas of expertise.

Erin Wright, PharmD, BCPS

Director, Field Pharmacy
Premier Inc.

Erin Wright, PharmD, BCPS, is a director with the field pharmacy team at Premier Inc. She is responsible for providing expertise regarding Premier's service and contract portfolios to Premier members and serves as the primary liaison on all pharmacy-specific initiatives. Dr. Wright serves Premier's field team as the clinical resource on biosimilars. She was a clinical and operations coordinator at a large academic medical center for 14 years before joining Premier in December 2019. Dr. Wright received her Doctor of Pharmacy from Purdue University and she is an active member of the American Society of Health System Pharmacists as well as the Florida Society of Health System Pharmacists.

AMCP STAFF & CONSULTANTS / THANK YOU

Susan A. Cantrell, RPh, CAE
Chief Executive Officer

Phil Bongiorno
Vice President, Policy & Government Relations

Thomas Casey
Senior Policy & Government Relations Coordinator

Liz Colangelo
Senior Manager, Business Strategies

Vyishali Dharbhamalla, PharmD
Manager, Professional Affairs

Abigail Fredenburg, MA
Director of Integrated Marketing & Communications

Julian Greer, CMP
Senior Manager, Meetings and Forums

Nicholas Ladikos, PharmD, BCPS, BCGP, BCIDP
Director of Professional Affairs

Cate Lockhart, PharmD, PhD
Executive Director

Matt Lowe
Vice President, Business Strategies

Noreen Matthews, BSN, MBA
Senior Business Consultant

Cynthia Reilly, MS, BS Pharm
Chief Operating Officer

Terry Richardson, PharmD, BCACP
Senior Pharmacist Consultant

Ruby Singh, PharmD, BCPS
Vice President, Education and Training

Thank You

To our distinguished participants and guests.

•

About AMCP

AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP's diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management, and help patients access cost-effective and safe medications and other therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.

•

AMCP Mission

To improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.

NOTES

AMCP

Optimizing medicine.
Improving lives.

AMCP | Academy of Managed Care Pharmacy

675 N Washington Street | Suite 220
Alexandria, VA 22314

703 684 2600 | www.amcp.org | @amcporg

Findings and recommendations from this event will be published in an upcoming issue of AMCP's *Journal of Managed Care + Specialty Pharmacy* and will be widely disseminated to decision makers around the country.